ASCO 2021

Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment

By

Sucharita Mistry, PhD

Younger patients had a significant decrease in sleep time on days they received dexamethasone.

Expanding Medicaid Eligibility May Improve Survival in Patients With Cancer

By

Jonathan Goodman, MPhil

Patients living in states with lower eligibility limits had worse survival rates, regardless of cancer stage at diagnosis.

A patient with cancer receives palliative care.

Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment

By

Joyce Pagan

Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.

Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD–driven AML.

Ivosidenib Plus Venetoclax, With or Without Azacitidine, Appears Effective in IDH1-Mutated Myeloid Malignancies

By

Colby Stong

The 1-year overall survival rate was 71%.

Results from the phase 3 Myeloma XI trial bolster earlier evidence that maintenance therapy with len

FORTE Study Compares Multiple Regimens in Patients With Multiple Myeloma With Cytogenetic Abnormalities

By

Jonathan Goodman, MPhil

Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.

$FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.$

Carfilzomib-Based Consolidation Regimen May Be Inferior to ASCT in Patients With Multiple Myeloma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Daratumumab Maintenance Shows Clinical Benefit in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

By

Lauren Dembeck, PhD

Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.

The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are re

Combination Therapy Shows Promise in Patients With Ultra High-Risk Multiple Myeloma, PCL

By

Jonathan Goodman, MPhil

Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

New C-CAR039 Therapy Is Safe and Effective in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell

Consolidation Therapy in Newly Diagnosed PCNSL Remains Undefined

By

Jonathan Goodman, MPhil

Researchers sought to determine whether myeloablative consolidation after induction therapy would improve PFS in patients with newly diagnosed primary central nervous system lymphoma.

A blood smear of chronic myeloid leukemia cells.

Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib

By

Jonathan Goodman, MPhil

Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.

Venetoclax and ibrutinib are therapeutic agents for CLL.

Ibrutinib, Venetoclax Combination Shows Promise in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether combination ibrutinib and venetoclax would have durable responses in patients with CLL and SLL.

An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.

Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment

By

Leah Lawrence

The model appears to predict minimal residual disease status.

CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy.

Phase 3 Trial Evaluating Venetoclax, Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.

A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.

Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL

By

Jonathan Goodman, MPhil

Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.

High levels of plasma total immunoglobulin E were associated with low risk of chronic lymphocytic le

Adding Ixazomib to Dexamethasone Does Not Improve PFS Compared to Pomalidomide in Multiple Myeloma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.

CAR-T Cell Therapy Shows Promise in Pretreated Patients With Multiple Myeloma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether cilta-cel would have clinical activity in patients with previously treated multiple myeloma.

Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.

Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects

By

Jonathan Goodman, MPhil

Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.

Enasidenib With Azacitidine May Improve Survival in Patients With IDH2-Mutated Myelodysplastic Syndrome

By

Jonathan Goodman, MPhil

Researchers sought to determine whether enasidenib combined with azacitidine may increase survival in patients with IDH2-mutated myelodysplastic syndrome.

Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia

By

Leah Lawrence

Eight patients had a complete response within 1 month of infusion.

Want to read more?